Mitochondrial involvement in schizophrenia and other functional psychoses

Area of Science:

• Neuroscience
• Molecular Biology
• Psychiatry

Background:

• Gene expression studies in post-mortem brain tissue are crucial for understanding complex neurological disorders.
• Previous research has explored genetic and molecular alterations in schizophrenia and depressive illness, but mitochondrial involvement remains an area of active investigation.

Purpose of the Study:

• To investigate alterations in gene expression in the frontal cortex of patients with schizophrenia and depressive illness.
• To identify specific genes and pathways affected in these conditions, with a focus on mitochondrial gene products.
• To examine the influence of neuroleptic medication on mitochondrial gene expression in experimental models.

Main Methods:

• Extraction and characterization of mRNA from post-mortem frontal cortex samples.
• Differential screening of cDNA libraries to identify differentially expressed genes.
• Sequencing of identified clones to determine their genetic identity, with a focus on mitochondrial transcripts.
• Enzymatic activity assays for mitochondrial respiratory chain complexes.

Main Results:

• Four mitochondrial transcripts, including mitochondrial ribosomal RNA (rRNA) and cytochrome oxidase subunit II (COX II), were found at reduced levels in schizophrenic samples.
• Neuroleptic administration in animal models led to decreased levels of several mitochondrial transcripts, including those encoding respiratory enzymes.
• Schizophrenic patients exhibited altered NADH-cytochrome c reductase activity, with reduced rotenone-sensitive activity compensated by increased rotenone-insensitive activity.

Conclusions:

• Changes in mitochondrial gene expression are significantly involved in the pathophysiology of schizophrenia and potentially other functional psychoses.
• Mitochondrial dysfunction, particularly in respiratory chain complexes, may contribute to the neurobiological deficits observed in schizophrenia.
• Neuroleptic medications can influence mitochondrial gene expression, suggesting a complex interplay between treatment and cellular metabolism in psychosis.